32Co Expands Comprehensive UK Sleep Clinic Network to Address Escalating Sleep Disorder Predicament

32Co Expands Comprehensive UK Sleep Clinic Network to Address Escalating Sleep Disorder Predicament

The UK-based healthtech company, 32Co, is set to revolutionise the landscape of sleep apnoea and snoring treatment with the launch of its nationwide network of Aerox Sleep Centres this summer. The initial locations include London, Manchester, Edinburgh, and Bristol, with plans to expand further.

The expansion aims to address the growing crisis of obstructive sleep apnoea (OSA) and problematic snoring by improving patient access to effective treatment and upskilling dentists in these disorders. Aerox Sleep Centres will provide local, specialist care with custom-made treatment devices, primarily Mandibular Advancement Devices (MADs), which have demonstrated effectiveness in treating sleep-related breathing disorders.

Traditional over-the-counter solutions for snoring have failed to address the root cause, but MADs work by advancing the lower jaw forward to keep the airway open during sleep, reducing obstruction and snoring. They are well-recognised as a non-invasive alternative to CPAP machines, particularly for mild to moderate OSA, improving sleep quality and reducing associated health risks.

The Aerox Sleep Centres will focus on treating patients with mild to moderate OSA and problematic snoring. From a dental upskilling perspective, 32Co is training dentists to specialise in OSA and snoring treatment, advancing their competencies in diagnosis and management with devices like MADs. Aerox’s Clinical Lead, Professor Ama Johal, an expert with a PhD on mandibular advancement splints, is spearheading this education, ensuring treatments are evidence-based and clinically effective.

Professor Johal's involvement underscores the clinical credibility of MADs in treating these disorders. In pre-pilot trials, these sleep centres and MADs have helped hundreds of patients improve their sleep. Michael, 58, from London, reported waking up with less tiredness and grumpiness since using the sleep devices, while John, 69, from Manchester, stated that he would sleep downstairs with the dog if his device broke.

Snoring can lead to chronic sleep disruption, which is linked to depression, memory loss, diabetes, and fatigue-related accidents. With around 8 million people aged 30-69 years potentially affected by OSA in the UK alone (Lancet, 2020), and a further 1 in 4 people snoring or snoring problematically, the need for accessible and effective treatment is evident.

Aerox Sleep Centres exemplify an integrated market innovation in the UK sleep disorder treatment landscape by expanding local access to specialist OSA and snoring care through dental practices, upskilling dentists using expert-led programs for disease management with oral devices, and utilising mandibular advancement devices, which have demonstrated effectiveness in treating sleep-related breathing disorders.

This development may reshape how OSA and snoring are managed outside traditional hospital or sleep clinic settings, potentially improving outcomes and patient convenience. The industry standard treatment method against sleep apnea is via CPAP machine, but many patients find it uncomfortable and difficult to travel with. With MADs being more adhered to by patients compared to Continuous Positive Airway Pressure (CPAP) machines, this innovation could offer a more comfortable and convenient solution for many.

The trend of 'sleep divorces', where partners sleep in separate rooms due to snoring, could also be alleviated with the widespread availability of MADs through Aerox Sleep Centres. For those consistently sleeping in another room due to sleep issues, such as 19% of millennials and 14% of Gen Z, this innovation could bring them back to shared slumber.

In conclusion, the expansion of Aerox Sleep Centres by 32Co across the UK represents a significant step forward in addressing the growing crisis of OSA and problematic snoring. By improving patient access to specialist care, upskilling dentists in OSA and snoring treatment, and utilising effective, non-invasive treatment devices like MADs, 32Co is set to reshape the sleep disorder treatment landscape in the UK.

[1] 32Co press release, 2023.

1. In the UK, 32Co is launching a network of Aerox Sleep Centres to revolutionise sleep apnoea and snoring treatment this summer.
2. The initial locations are London, Manchester, Edinburgh, and Bristol, with plans for expansion.
3. The aim is to address the rising crisis of obstructive sleep apnoea (OSA) and problematic snoring by improving patient access to effective treatment.
4. Aerox Sleep Centres will offer local, specialist care with custom-made Mandibular Advancement Devices (MADs).
5. Traditional over-the-counter solutions for snoring have failed to address the root cause, but MADs do.
6. MADs work by advancing the lower jaw forward to keep the airway open during sleep, reducing obstruction and snoring.
7. MADs are a non-invasive alternative to CPAP machines, particularly for mild to moderate OSA.
8. The Aerox Sleep Centres will focus on treating patients with mild to moderate OSA and problematic snoring.
9. 32Co is training dentists to specialise in OSA and snoring treatment, advancing their competencies.
10. Professor Ama Johal, an expert with a PhD on mandibular advancement splints, is leading the education.
11. Pre-pilot trials show that these sleep centres and MADs have helped hundreds of patients improve their sleep.
12. Snoring can lead to chronic sleep disruption, linked to depression, memory loss, diabetes, and fatigue-related accidents.
13. Around 8 million people aged 30-69 years might be affected by OSA in the UK alone (Lancet, 2020).
14. A further 1 in 4 people snore or snore problematically.
15. The need for accessible and effective treatment is evident, and Aerox Sleep Centres are filling this gap.
16. Aerox Sleep Centres exemplify an integrated market innovation in the UK sleep disorder treatment landscape.
17. This innovation could offer a more comfortable and convenient solution for many, as MADs are more adhered to by patients compared to CPAP machines.
18. The trend of 'sleep divorces' could be alleviated with the widespread availability of MADs through Aerox Sleep Centres.
19. For those consistently sleeping in another room due to sleep issues, this innovation could bring them back to shared slumber.
20. The expansion of Aerox Sleep Centres by 32Co represents a significant step forward in addressing the growing crisis of OSA and problematic snoring.
21. By improving patient access to specialist care, upskilling dentists, and utilising effective, non-invasive treatment devices like MADs, 32Co is reshaping the sleep disorder treatment landscape in the UK.
22. Many patients find CPAP machines uncomfortable and difficult to travel with, making MADs a potential solution.
23. The development may reshape how OSA and snoring are managed outside traditional hospital or sleep clinic settings.
24. Improved outcomes and patient convenience could result from this change in management.
25. This innovation could be a game-changer in digital health, as it integrates technology with healthcare services.
26. Sleep is essential for overall health and wellness, fitness and exercise, and cardiovascular health.
27. Good sleep can also improve skin care, helping to reduce the signs of premature ageing.
28. From a lifestyle perspective, better sleep can lead to improved relationships and even reduce stress levels.
29. Apart from MADs, other therapies and treatments, nutrition, and CBD products can also contribute to overall health and wellness, including healthy cooking, skincare products, and pet care.

Read also: